The insight mainly analyzed the relationship of drug spending with GDP growth, different logic behind China/US biotech companies and related risks when buy the dip,and low risks of VBP on anesthetics.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.